An estimated 7,000 people are bitten by rattlesnakes, copperheads and cottonmouths in the U.S. each year. Patients who do not receive quick and appropriate treatment risk permanent damage to their skin, tissue, limb function and vital organs.
BTG’s CroFab is the only FDA-approved treatment for snake bites. To ensure hospitals maintain adequate inventory and have access to CroFab when needed, the pharmaceutical company has partnered with OMNY to track near real-time data about CroFab stock levels across participating healthcare institutions.
BTG and the Rocky Mountain Poison and Drug Center in Denver will securely capture this data, with the goal to eventually expand the offering to additional healthcare organizations and poison control centers.
“As an emergency medicine physician, I’ve experienced first-hand how difficult it is to provide patient care without access to the treatment,” said OMNY co-founder and CEO Mitesh Rao, MD. “Our platform’s ability to quickly and securely share data and ensure its provenance for all involved can ensure hospitals are adequately stocked, and poison control centers like RMPDC can help coordinate care for hospitals and first responders.”
More articles on supply chain:
Novartis, VC firms invest $64M in ‘digital therapeutics’ company
Non-acute supply chain — Opportunities and considerations for C-level leaders
Red Cross offers Dunkin’ gift cards to blood donors amid winter shortage
